We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Stockal+Disclaimer.pdf
4 own
6 watching
Current Price
$0
$-0.09
(-0.46%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
960.37M
52-Week High
26.25
52-Week Low
3.965
Average Volume
0.02M
Dividend Yield
--
P/E Ratio
--
Market Capitalization960.37M
52-Week High26.25
52-Week Low3.965
Average Volume0.02M
Dividend Yield--
P/E Ratio--
What does the Stockal+Disclaimer.pdf do?
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
Zolmax
29days ago
Pliant Therapeutics, Inc. (NASDAQ:PLRX Get Rating) insider Eric Lefebvre sold 5,000 shares of the firms stock in a transaction on Tuesday, October 25th. The shares were sold at an average price of $25.05, for a total transaction of $125,250.00. Following the sale, the insider now owns 133,437 shares...
Globe Newswire
3 months ago
SOUTH SAN FRANCISCO, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M.D., Ph.D., President and ...
Zolmax
4 months ago
SVB Leerink assumed coverage on shares of Pliant Therapeutics (NASDAQ:PLRX Get Rating) in a research note issued to investors on Wednesday morning, The Fly reports. The brokerage issued an outperform rating and a $33.00 target price on the stock. A number of other analysts also recently commented on...
Ticker Report
4 months ago
SVB Leerink assumed coverage on shares of Pliant Therapeutics (NASDAQ:PLRX Get Rating) in a research note issued to investors on Wednesday morning, The Fly reports. The brokerage issued an outperform rating and a $33.00 target price on the stock. A number of other analysts also recently ...
Zolmax
4 months ago
Pliant Therapeutics (NASDAQ:PLRX Get Rating) had its target price increased by Piper Sandler from $27.00 to $40.00 in a report published on Monday, The Fly reports. A number of other analysts have also recently issued reports on the company. Cantor Fitzgerald raised their price objective on ...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$-0.09
(-0.46%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00